Oncolytics Biotech Inc SEC filings ONCY
Oncolytics Biotech Inc has 1,000 filings in SEC EDGAR's recent list, going back to Jan 31, 2008. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 3 | Initial insider ownership | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 3 | Initial insider ownership | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Jun 3, 2026 | Jun 1, 2026 |
| 4 | Insider transaction | Mar 13, 2026 | Mar 11, 2026 |
| 4 | Insider transaction | Mar 13, 2026 | Mar 12, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 11, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 11, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 11, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| 4 | Insider transaction | Jan 20, 2026 | Jan 16, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| 3 | Initial insider ownership | Jan 2, 2026 | Jan 1, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | May 10, 2011 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2011 | — |
| SC 13G | Ownership over 5% (passive) | Feb 10, 2011 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jun 10, 2008 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2008 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1129928
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.